MaaT Pharma, Leader in Development of Microbiome-Based Therapies in Oncology, Awarded Government Funding for Clinical Development of MaaT033 as part…
Categorie
Financial
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of the General…
November 13, 2023
MaaT Pharma Provides Third Quarter 2023 Business Update and Reports Financial Results Independent Data Safety Monitoring Board (DSMB) reviewing the…
November 9, 2023
MaaT Pharma: Increase in Resources Allocated to the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux Lyon, France, October 9,…
October 9, 2023
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of the General…
October 6, 2023
MaaT Pharma Publishes its Half Year 2023 Results and Provides a Business Update The ARES study on MaaT013 reached the…
September 26, 2023
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.